Vaccine molecules

Patent metadata

Field	Value
Publication number	US-12447205-B2
Application number	US-202418738696-A
Country	US
Kind code	B2
Filing date	Jun 10, 2024
Priority date	Sep 7, 2017
Publication date	Oct 21, 2025
Grant date	Oct 21, 2025

Abstract

Provided herein is technology relating to vaccines and particularly, but not exclusively, to compositions, methods, and uses of a mixture of immunogenic vaccine molecules comprising components for targeting the dimeric vaccine molecules to antigen-presenting cells and components for eliciting an immunogenic response, wherein the components for eliciting an immunogenic response preferably comprise at least three variants of an immunogenic protein, such as variants of immunogenic proteins obtained from three or more different strains of a pathogenic organism.

First claim

We claim:

1. A vaccine composition comprising a mixture of multimeric protein molecules, wherein said mixture of multimeric protein molecules comprise a mixture of at least 3 different fusion protein monomers comprising a targeting unit, a multimerization domain, and an antigenic unit in operable association, wherein said antigenic unit for each of said three different fusion protein monomers differ by encoding different variant target antigenic proteins, and wherein said multimeric protein molecules comprise at least two of said monomers joined by association of said multimerization domains.

2. The vaccine composition of claim 1 , wherein said multimeric protein molecule is a dimeric protein molecule and multimerization domain is a dimerization domain.

3. The vaccine composition of claim 2 , wherein said multimerization domain is a hinge/C H 3 dimerization domain.

4. The vaccine composition of claim 1 , wherein said targeting unit is an antigen binding protein.

5. The vaccine composition of claim 4 , wherein said antigen binding protein is an scFv.

6. The vaccine composition of claim 1 , wherein said targeting unit is an Antigen Presenting Cell (APC) targeting unit.

7. The vaccine composition of claim 6 , wherein said APC targeting unit binds to a target selected from the group consisting of MHC-II molecules, CD40, CD14, HLA-DP, Toll-like receptors, and chemokine receptors.

8. The vaccine composition of claim 1 , wherein said different variant antigenic target proteins have greater than about 30%, 40%, 50%, 60%, 70%, 80%, 90% or 95% sequence identity.

9. The vaccine composition of claim 1 , where said different variant antigenic target proteins are from different strains of an organism.

10. The vaccine composition of claim 9 , wherein said organism is a pathogenic organism.

11. The vaccine composition of claim 10 , wherein said pathogenic organism is selected from the group consisting of a virus, a bacterium, a fungus and a protozoan.

12. The vaccine composition of claim 1 , wherein said different variant antigenic target proteins are variants of hemagglutinin (HA).

13. The vaccine composition of claim 12 , wherein said vaccine comprises variants of HA from at least three, four, five or six strains of influenza viruses.

14. The vaccine composition of claim 13 , wherein said influenza viruses are group 1 influenza viruses.

15. The vaccine composition of claim 14 , wherein said group 1 influenza viruses are selected from the group consisting of H5, H6, H8, H9, H11, and H13.

16. The vaccine composition of claim 1 , wherein said different variant antigenic target proteins are variants of a cancer antigen.

17. The vaccine composition of claim 2 , wherein said mixture of dimeric protein molecules comprises a defined number of different dimeric molecules, where said defined number of different dimeric molecules is calculated by the formula [n(n+1)]/2 where n is the number of different variant antigenic target proteins.

18. The vaccine composition of claim 17 , wherein the number of different dimeric molecules is 6 when n is 3, 10 when n is 4, 15 when is n 5 and 21 when n is 6.

19. A pharmaceutical formulation comprising the vaccine composition of claim 1 and a pharmaceutically acceptable carrier.

20. A vaccine formulation comprising a vaccine composition of claim 1 and an adjuvant.

21. A method of immunizing or inducing an immune response to variant target antigenic proteins in a subject comprising administering to said subject a vaccine composition according to claim 1 to a subject.

Assignees

• Univ Oslo

Inventors

• Grødeland Gunnveig
• Bogen Bjarne
• Anderson Ane Marie

Classifications

• C12N2760/16134

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title

• C07K2319/40

  containing a tag for immunodetection, or an epitope for immunisation · CPC title

• C07K2319/33

  fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies · CPC title

• C07K2317/622

  Single chain antibody (scFv) · CPC title

• C07K2317/53

  Hinge · CPC title